恒指季检揭盅蓝筹股不变 国指加入中生制药及润燃 剔出中铁及中建材
恒生指数公司今日(8日)宣布,截至2019年9月30日之恒生指数系列季度检讨结果,有关变动将於2019年12月9日(星期一)起生效。
恒生指数成份股没有变动,成份股数目固定为50只。
另恒生中国企业指数成份股将加入中国生物制药(01177.HK)及华润燃气(01193.HK);剔出中铁(00390.HK)及中国建材(03323.HK)。
此外,根据季度快速纳入机制,恒生综合大中型股指数成份股将有以下的变动,成份股数目将由302只增加至303只。是次加入中梁控股(02772.HK)。
就恒生指数公司计划进行有关恒生指数的市场谘询,该谘询将涵盖多项议题,例如各类型股票,例如同股不同权公司,是否符合被纳入指数的资格及指数中金融业的权重问题等。谘询预计於2020年首季进行,而有关谘询结果则於2020年5月公布。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.